Analysis Life Sciences Thank You Everything the FDA is planning to do in Q3 2023
Agency IQ
JULY 28, 2023
On March 27, the FDA finalized a transition guidance document covering products that had been marketed under enforcement discretion policies during the PHE. First, by March 2021, manufacturers were expected to conclude a risk assessment of their approved or marketed products to assess the risk of nitrosamines.
Let's personalize your content